Dr Arvind Parmar

 

Arvind’s primary responsibility at ANSTO is to apply in vivo, ex vivo and in vitro techniques to the investigation of diseases (onset, progression, regression) in preclinical models for the purpose of improving diagnostic and therapeutic tools in various clinical fields mainly cancer, CVS and metabolic disorders using multi-modality pre-clinical imaging systems such as PET/CT and SPECT/CT.

 

He also acts as a deputy Quality co-ordinator within ANSTO LifeSciences. 

 

 

After working for 2 years at AstraZeneca, UK, as an imaging scientist, Arvind joined ANSTOLifeSciences in May 2011. His main expertise is in vivo small animal imaging.

 

He has worked for over a decade on various pharmacological disease models, mainly on cancer, infectious diseases and inflammation. He did his Master of Pharmacy in Pharmacology in 2001 at the M S University, India, and was initially employed for three years in the Sun Pharma Advance research centre, India. 

 

He completed his PhD in Pharmacology at M S University, India in 2006. He joined the School of Medicine at the University of Manchester as a Post-Doctoral Research Scientist in 2006 and worked there for 3 years. The project involved pharmacodynamic and pharmacokinetic studies of novel antimicrobial drugs.

 

 

Arvind’s expertise lies in molecular imaging using PET/CT, SPECT/CT, ultrasound, and optical imaging of preclinical disease models, and checking novel imaging biomarkers for POP /POC using in vivo studies. 

 

 

Imaging Physiologist (2011-Current)

Post doc Fellow, Manchester University, UK (2006-2008)

PhD in Pharmacology, M. S. University, India (2006)